Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug shows promise in early cancer trial

NCT ID NCT02937272

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 adults whose cancer has not responded to standard therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3200882 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for certain solid tumors.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet proven to work. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 223 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2016

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets. Exclusion Criteria: * Have moderate or severe cardiovascular disease. * Have a serious concomitant systemic disorder. * Have acute leukemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Camurati-Engelmann Syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor

Contacts and locations

Locations

  • CHRU de Lille

    Lille, 59037, France

  • Calvary Mater Newcastle

    Newcastle, New South Wales, 2298, Australia

  • Charité Campus Virchow-Klinikum

    Berlin, 12203, Germany

  • Greenslopes Private Hospital

    Greenslopes, Queensland, 4120, Australia

  • Gustave Roussy

    Villejuif, 94805, France

  • Hopital Saint-Louis

    Paris, Cedex 10, 75475, France

  • Hospital Clínico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Istituto Clinico Humanitas

    Rozzano, Milano, 20089, Italy

  • National Cancer Center Hospital

    Chuo-Ku, Tokyo, 104-0045, Japan

  • Ospedale Policlinico Giambattista Rossi, Borgo Roma

    Verona, 37134, Italy

  • Princess Margaret Hospital (Ontario)

    Lai Chi Kok, Kowloon, Canada

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, 2010, Australia

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Universitätsklinikum Würzburg A. ö. R.

    Würzburg, Bavaria, 97080, Germany

  • Weill Cornell Medical College

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.